Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
Status:
NOT_YET_RECRUITING
Trial end date:
2038-10-01
Target enrollment:
Participant gender:
Summary
This is a trial to compare neurocognitive outcomes in the intent-to-treat population 2.5 years after diagnosis between patients with newly diagnosed, non-metastatic, SHH-activated, TP53-wt, non-MYC amplified MF randomized to the interventional arms A ("Head Start 4") or B (HIT-SKK).
Phase:
PHASE3
Details
Lead Sponsor:
Nationwide Children's Hospital
Collaborators:
Children's of Alabama German Society of Paediatric Oncology and Hematology (GPOH gGmbH)